<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565005</url>
  </required_header>
  <id_info>
    <org_study_id>P 100128</org_study_id>
    <nct_id>NCT01565005</nct_id>
  </id_info>
  <brief_title>Microcephaly Genetic Deficiency in Neural Progenitors</brief_title>
  <acronym>MICROFANC</acronym>
  <official_title>Microcephaly Genetic Deficiency in Neural Progenitors: Genotyping, Phenotyping and Functional Neuro-anatomy and Neurobiology Comparative Primitive Microcephaly (MCPH) and the Fanconi Anemia (FA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to:&#xD;
&#xD;
      I. Compare neuroradiological phenotype and cognitive functioning of MCPH patients caused by&#xD;
      ASPM mutations already characterized and published (Passemard et al. 2009a) with other&#xD;
      MCPH-related patients (patients with MCPH1, WDR62, CDK5RAP2, CEP 152, CENPJ, STIL, or PCNT&#xD;
      mutations)&#xD;
&#xD;
      II. Describe the neuro-radiological and cognitive phenotype of microcephalic patients&#xD;
      suffering from Fanconi anemia, and compared them to subjects with:&#xD;
&#xD;
        -  Fanconi anemia but normal OFC (head circumference)&#xD;
&#xD;
        -  MCPH patients&#xD;
&#xD;
        -  Healthy control subjects Our hypothesis is that mutations in genes responsible of&#xD;
           microcephaly impact differentially cortical brain development and functioning&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phenotyping study on 2 different cohorts of rare disease affected patients:&#xD;
&#xD;
        -  Group1: MCPH (including different MCPH subtypes)&#xD;
&#xD;
        -  Group2: Fanconi Anemia (with or without microcephaly)&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      Common to each group:&#xD;
&#xD;
        -  Age &gt; 3 years&#xD;
&#xD;
        -  Access to french &quot;Social Security&quot;&#xD;
&#xD;
        -  No contraindication for MRI&#xD;
&#xD;
      Group1:&#xD;
&#xD;
        -  Primary microcephaly without gross malformation within or extra nervous central system&#xD;
&#xD;
        -  OFC &lt; -2SD at birth and &lt; -3 SD after age 6months&#xD;
&#xD;
        -  Mutation in one MCPH gene&#xD;
&#xD;
      Group2:&#xD;
&#xD;
      Proven Fanconi Anemia with:&#xD;
&#xD;
        -  Positive chromosome breakage blood test&#xD;
&#xD;
        -  One of the 3 following elements:&#xD;
&#xD;
      FANCD2 positive test Fibroblast sensitivity to mitomycin Mutation in one FANC gene&#xD;
&#xD;
      Control subjects:&#xD;
&#xD;
        -  No antecedent&#xD;
&#xD;
        -  Normal education&#xD;
&#xD;
      Aims:&#xD;
&#xD;
        1. Description of neurological, neuropsychological and radiological phenotype for each&#xD;
           group&#xD;
&#xD;
        2. Phenotype comparison:&#xD;
&#xD;
             -  groups 1&amp;2&#xD;
&#xD;
             -  group1 or 2 with control subjects&#xD;
&#xD;
             -  different MCPH subtypes within group1&#xD;
&#xD;
             -  with or without microcephaly within group2&#xD;
&#xD;
        3. Epidemiological data on these rare diseases in our population&#xD;
&#xD;
      Protocol:&#xD;
&#xD;
      Patients from both groups and control subjects will be evaluated in CIC for 1 day ½. They&#xD;
      will be examined by a child neurologist and a geneticist. All of them will have cranial MRI&#xD;
      (1.5Tesla). Neuropsychological assessment will be performed (Wechsler scales) for patients&#xD;
      and control subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare neuroradiological phenotype and cognitive functioning with other MCPH-related patients</measure>
    <time_frame>3 years</time_frame>
    <description>The purpose of this study is to:&#xD;
Compare neuroradiological phenotype and cognitive functioning of MCPH patients caused by ASPM mutations already characterized and published (Passemard et al. 2009a) with other MCPH-related patients (patients with MCPH1, WDR62, CDK5RAP2, CEP 152, CENPJ, STIL, or PCNT mutations)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish a clear organizational chart for the diagnosis of primary microcephaly</measure>
    <time_frame>3 years</time_frame>
    <description>I. Establish a clear organizational chart for the diagnosis of primary microcephaly from the detailed description of the patient's phenotype&#xD;
II. Establish epidemiological data on the molecular genetic causes involved in human primary microcephaly</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">98</enrollment>
  <condition>Microcephaly</condition>
  <arm_group>
    <arm_group_label>Microcephaly</arm_group_label>
    <description>Microcephaly Intellectual abilities Cranial MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FANCONI ANEMIA</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Group1:&#xD;
&#xD;
          -  Primary microcephaly without gross malformation within or extra nervous central system&#xD;
&#xD;
          -  OFC &lt; -2SD at birth and &lt; -3 SD after age 6months&#xD;
&#xD;
          -  Mutation in one MCPH gene&#xD;
&#xD;
        Group2:&#xD;
&#xD;
        Proven Fanconi Anemia with:&#xD;
&#xD;
          -  Positive chromosome breakage blood test&#xD;
&#xD;
          -  One of the 3 following elements:&#xD;
&#xD;
        FANCD2 positive test Fibroblast sensitivity to mitomycine Mutation in one FANC gene&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients aged ≥ 3 years:&#xD;
&#xD;
          -  Microcephalic phenotype consistent with MCPH (recruitment already done as part of a&#xD;
             network GIS-Rare Diseases Institute). MCPH patients have already been selected in the&#xD;
             cohort &quot;Robert Debré.&quot;&#xD;
&#xD;
          -  Holders of a Fanconi anemia characterized in terms of cytogenetics, enzyme and/or&#xD;
             molecular (patients in the cohort &quot;Saint Louis&quot; followed by the KRC rare aplastic&#xD;
             anemia)&#xD;
&#xD;
          -  Healthy controls aged ≥ 5 years siblings of patients with Fanconi Anemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with Fanconi anemia:&#xD;
&#xD;
          -  bone marrow &lt; 3 years&#xD;
&#xD;
          -  Post-transplantation neurological complications&#xD;
&#xD;
          -  developmental, genetic or environmental additional pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain VERLOES, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Parsi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Debre Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MCPH</keyword>
  <keyword>FANCONI ANEMIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Microcephaly</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

